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The expression of two cardiac myosin heavy chain (MyHC) isoforms in response to the thyroid status was studied in left ventricles
(LVs) of Lewis rats. Major MyHC isoform in euthyroid and hyperthyroid LVs had a higher mobility on SDS-PAGE, whereas
hypothyroid LVs predominantly contained a MyHC isoform with a lower mobility corresponding to that of the control soleus
muscle. By comparing the MyHC proﬁles obtained under altered thyroid states together with the control soleus, we concluded
that MyHCα was represented by the lower band with higher mobility and MyHCβ by the upper band. The identity of these two
bands in SDS-PAGE gels was conﬁrmed by western blot and mass spectrometry. Thus, in contrast to the literature data, we found
that the MyHCα possessed a higher mobility rate than the MyHCβ isoform. Our data highlighted the importance of the careful
identiﬁcation of the MyHCα and MyHCβ isoforms analyzed by the SDS-PAGE.
1.Introduction
Cardiac muscle contractility and its eﬃciency depend on
myosin heavy chain (MyHC) isoforms being present. Mam-
malian heart muscle cells express two MyHC gene products,
Myh6 and Myh7, which correspond to the α and β isoforms
respectively [1]. The molecular masses of the rat α and β iso-
forms are both about 223kDa (Rat Gene Database:
http://rgd.mcw.edu/), and their amino acid sequences are
93% identical [2]. However, the isoforms diﬀer in their
ATPase activity and in their eﬀect on heart contractility.
MyHCα represents a “fast myosin” with higher ATPase acti-
vity and faster contraction, whereas MyHCβ represents a
“slow myosin” with lower ATPase activity and slower contra-
ction [3–5]. In cardiac left ventricles (LVs), the α and β iso-
formsconstitutethreefunctionaldimersmarkedV1,V2,and
V3. V1 is the αα homodimer, while V3 is the ββ homo-
dimer, and V2 is the αβ heterodimer. The ATPase activity of
these three dimers corresponds to the α and β subunits in-
volved [3, 6, 7]. The variations in the V-type ratio
(V1:V2:V3) correlate with the heart rate of diﬀerent species
[7, 8]. Fast-contracting ventricles of mice and rats (heart
rate > 300/min) have a high proportion of V1, while slow-
contracting ventricles of humans and cows (heart rate about
70/min) contain a V3 majority. Rabbit and guinea pig ven-
tricles, with an intermediate speed, consist predominantly of
V3 and still possess some V1 and V2 dimers [9]. In vitro ex-
perimentsshowedthediﬀerenceinthehydrolyticandkinetic
characteristics of the two α and β isoforms, which could ex-
plain the diﬀerence in the economy of force development
and the basis for cardiac adaptation mechanism [10, 11]. In
general, the experimental evidence suggests that hearts ex-
pressing primarily MyHCαisoformhavea signiﬁcantlyhigh-
er rate of muscle shortening, whereas the hearts expressing
mostly MyHCβ possess the ability to generate force with
higher eﬃciency [12].
The amount and changes in the ratio of V dimers have
been determined using native gel electrophoresis under non-
denaturating conditions, and it was found that the myosin2 Journal of Biomedicine and Biotechnology
dimers mobility decreases in order V1 > V2 > V3 [6–8, 13–
16]. On the other hand, the experiments studying the mobil-
ity of individual α and β monomers by the sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
under denaturing conditions showed lower mobility of
MyHCα compared to MyHCβ [17–24].
The relative proportion of α and β isoforms in cardiac
LVs can be inﬂuenced by several physiological and patho-
physiological factors like hemodynamic overload, diabetes,
or thyroid hormones, and it also corresponds with heart ﬁt-
ness [12]. Thyroid hormones were found to be the most po-
tent regulators of cardiac MyHC gene expression [25]. In-
creased levels of thyroid hormones stimulate MyHCα (V1)
and restrain MyHCβ (V3) expression leading to the hyper-
thyroidphenotype,whileloweredlevelsofthyroidhormones
result in the inhibition of MyHCα (V1) and activation of
MyHCβ (V3) expression resulting in the hypothyroid phe-
notype[26–32].Alterationstothethyroidhormonelevels,in
both experimental animals and humans, contribute to vari-
ous pathological changes including some of the most life-
threatening cardiac events, like atrial and ventricular ﬁbrilla-
tionsormalignantventriculararrhythmias[33–35].Changes
in the expression of cardiac MyHC isoforms are supposed to
betheimportantaspectofafailingheart[36,37].Sincemany
cardiovasculardiseases are accompaniedby the shift between
cardiac α and β MyHC isoforms, the unequivocal determi-
nation of both isoforms separated by SDS-PAGE is extremely
important, even for human pathology.
In this study, we present data on the MyHC isoforms
mobility obtained by SDS-PAGE technique and unambigu-
ous identiﬁcation of α and β isoforms by mass spectrometry
(MALDI TOF/TOF) [38] and western blot (WB) analyses.
2.MaterialandMethods
2.1. Animals. Male and female 4-week-old inbred Lewis
strainratsobtainedfromanauthorizedlaboratoryoftherat-
breeding unit of the Institute of Physiology, Academy of
Sciences of the Czech Republic, v. v. i., Prague, Czech Repub-
lic (accreditation no. 1020/491/A/00) were used for the ex-
periments. Male euthyroid 250g Wistar rats, obtained from
Velaz s.r.o., Prague, Czech Republic, were used for compari-
son to the experimental Lewis strain rats. The maintenance
andhandlingoftheexperimentalanimalswereinaccordance
with the EU Council Directive (86/609EEC) as well as with
the local ethical committee guidelines of the Czech Ministry
of Agriculture no. 1020/437/A/99. The investigation was ap-
proved by the Expert Committee of the Institute of Physiolo-
gy,AcademyofSciencesoftheCzechRepublic,v.v.i.,Prague,
Czech Republic.
2.2. Alteration of Thyroid Status. The hyperthyroid status
(TH) was induced by intraperitoneal injections of 3,3 ,5-tri-
iodo-L-thyronine (sodium salt, T3, 150μg/kg body weight)
three times a week to the 4-week-old animals for 3 to 10
months. The hypothyroid (HY) status was induced with
a 0.05% solution of methimazole (2-mercapto-1-methyl-
imidazole) in drinking water given to the rats from the age
of 4 weeks for 4 to 11 months. The euthyroid (EU) rats were
age-matched littermates of the experimental animals. All the
rats analyzed in this study were part of a larger group in
whichthyroidstateswerepreviouslycheckedbythemeasure-
ment of biochemical and anatomical parameters that are
known to be aﬀected by thyroid hormone level alterations
[39, 40].
2.3. Tissue Preparation. Cardiac tissue was obtained from
adult EU, HY and TH inbred Lewis male and female rats.
LVs from Wistar rats were used as a control of the MyHC
band position in order to exclude strain diﬀerences. The ani-
mals were anesthetized with intraperitoneal injections of
1mL (100mg) of Narketan (Ketaminum ut hydrochlori-
dum) per 1000g of body weight, followed by 0.5mL (10mg)
of the myorelaxant Xylapan (Xylazinum ut hydrochloridum)
per 1000g of body weight (Vetoquinol SA, France, and Veto-
quinol Biowet, Poland, resp.). Whole hearts were quickly ex-
cised and placed in iced saline solution. LVs were readily iso-
lated and immediately frozen in liquid nitrogen. Control
soleus muscles (SOL) were excised immediately after the
heartsandfurthertreatedwiththesameproceduredescribed
for LVs.
2.3.1. Homogenate Adjustment. The frozen LVs were pulver-
ized in liquid nitrogen using porcelain mortar and homo-
genized 1:40 (w/v ratio) with homogenization buﬀer
(5Murea, 2Mthiourea, 0.4M DL-dithiothreitol (DTT),
10mM sodium pyrophosphate tetrabasic decahydrate) using
a glass/glass homogenizer. The LV homogenates were ali-
q u o t e da n ds t o r e da t−80◦C. Deep frozen tissue treatment
and highly denaturating homogenization buﬀer protected
proteins against eventual protease activity.
2.3.2. MyHC Extraction. T h eM y H Ce x t r a c t i o nw a sp e r -
formed according to Agbulut et al. [41]. The LVs were pul-
verized in liquid nitrogen using a porcelain mortar. The
powder was transferred into iced extraction buﬀer pH 6.5
containing 300mM NaCl, 0.1M NaH2PO4 monohydrate,
50mM Na2HPO4 anhydrous, 10mM sodium pyrophos-
phate, 1mM MgCl2, 10mM EDTA, and fresh 1.4mM mer-
captoethanol. MyHC were extracted for 1 hour on ice using
four volumes of extraction buﬀer. The LV extracts were cen-
trifuged at 12000×gf o r1 0m i n u t e sa t4 ◦C and the super-
natants were diluted 1:1 (v/v ratio) with conservation buﬀer
pH 8.5 containing 40mM sodium pyrophosphate and 50%
glycerol, aliquoted and stored at −80◦C.
2.4. MyHCs Separation. The SDS-PAGE method was per-
formed on the Mini-PROTEAN Tetra Cell (BioRad) with gel
thickness 0.75mm according to a protocol used by
Sant’Ana Pereira et al. [22] for gels running at con-
stant current 13mA (no pulse) for 7.5 hours. Separat-
ing and stacking gels were prepared on the same day
as the electrophoresis was run. Separating gels (12%
ﬁnal concentration of acrylamide) contained 10% glyc-
erol (v/v ratio), 12% acrylamide/bisacrylamide solution
(the ratio of acrylamide/N,N -methylenebisacrylamide wasJournal of Biomedicine and Biotechnology 3
200:1), 750mM 2-amino-2-hydroxymethyl-propane-1,3-
diol (TRIS) (pH 9.3), 0.1% sodium dodecyl sulphate (SDS)
(w/v ratio), 0.03% ammonium persulphate (APS) (w/v
ratio), and 0.14% tetramethylethylenediamine (TEMED).
Stacking gels (3.7% ﬁnal concentration of acrylamide) con-
tained 10% glycerol, 3.7% acrylamide/N,N -methylene-bi-
sacrylamide (20:1 ratio), 125mM TRIS (pH 6.8), 0.1% SDS,
0.03% APS, and 0.3% TEMED. Electrode buﬀer was com-
posed of 0.05M TRIS, 0.38M glycine, and 0.346mM SDS.
Homogenates were diluted 1:1.5 (v/v ratio) with sample
buﬀer (0.125M TRIS pH 6.8, 0.5mM EDTA pH 7, 5% SDS,
15mM DTT, 20% glycerol, 0.1% Bromphenol Blue), LV ex-
tracts were diluted 1:1 (v/v ratio) with sample buﬀer, and
SOL extracts were diluted 1:19 (v/v ratio) with sample buf-
fer. Homogenates were loaded on the gels in the amount of
7μLpersample(5.5μgprotein),LVextractsintheamountof
15μL( 1 μg protein) per sample, and SOL extracts of 4μL
(2μg protein) per sample. As a control, we used SOL from
hypothyroid animals (HY), containing basically 100% of the
slow isoform identical with cardiac MyHCβ. The gels were
directly used for WB analyses or stained by a mixture of
Coomassie Brilliant Blue and Bismarck Brown R (CBB&
BBR)[42]formassspectrometryandstainedbysilvernitrate
for densitometry quantiﬁcation (Quantity One Software,
BioRad) [43].
2.5. MALDI TOF/TOF Sample Preparation. Each single
CBB&BBR stained protein band was cut out from a single
lane of the gel, placed to a microtube, and covered with
100μL 50mM ammonium bicarbonate (ABC) buﬀer in 50%
acetonitrile (ACN) with 50mM DTT. All samples were sub-
jected to sonication in an ultrasonic cleaning bath for 5 min-
utes.After15minutesthesupernatantwasdiscarded,andthe
gel was covered with 100μL of 50mM ABC/50% ACN with
50mM iodoacetamide and sonicated for 5 minutes. After 25
minutes, the supernatant was discarded and exchanged for
100μL 50mM ABC/50% ACN with 50mM DTT and soni-
cated for 5 minutes to remove any excess iodoacetamide. The
supernatant was discarded, and the samples were sonicated
for 5 minutes in 100μL of HPLC-grade water. The water was
discarded, and samples were sonicated for another 5 minutes
in 100μL of ACN. ACN was discarded, and the microtubes
with the samples were left open for a couple of minutes to
allow the rest of ACN to evaporate. Then, 5ng of trypsin
(Promega)in10μLof50mMABCwereaddedtothegel.The
samples were incubated at 37◦C overnight. Triﬂuoroacetic
acid(TFA)andACNwereaddedtotheﬁnalconcentrationof
1% TFA, 30% ACN. The samples were sonicated for 10 min-
utes, and a 0.5μL drop was transferred onto MALDI targets
and let to dry. The dried droplets were covered with a 0.5μL
drop of α-cyano-4-hydroxycinnamic acid solution (2mg/mL
in 80% ACN) and let to dry.
2.6. MALDI TOF/TOF Analysis. Peptide mapping was per-
formed in multiple independent experiments and indepen-
dent samples. Spectra were acquired in the range of 800–
3500m/z using a 4800 Plus MALDI TOF/TOF Analyzer
(Applied Biosystems/MDS Sciex) equipped with a Nd:YAG
laser (355nm, ﬁring rate 200Hz). Peak lists from the MS
spectra were generated by 4000 Series Explorer V 3.5.3 (Ap-
pliedBiosystems/MDSSciex)withoutsmoothing,peakswith
the local signal-to-noise ratio greater than 5 were picked
automatically, deisotoped, and searched with local Mascot v.
2.1 (Matrix Science) against the nonredundant NCBI data-
base of protein sequences as of 06/14/2010 (11186807 seq-
uences; 3815639892 residues). The database search criteria
wereasfollows—enzyme:trypsin,taxonomy:Rattusnorvegi-
cus (66703 sequences), ﬁxed modiﬁcation: carbamidomethy-
lation, variable modiﬁcation: methionine oxidation, peptide
mass tolerance: 80ppm, and one missed cleavage allowed.
Only the hits that were scored by the Mascot software as sig-
niﬁcant (P<0.0001) were accepted for further analyses.
2.6.1. Sequences Evaluation. Sequences for cardiac MyHC
were obtained from GenBank databases: (MyHCα) P02563
and (MyHCβ) P02564. Sequences were aligned with Clus-
talW 1.83: http://www.ebi.ac.uk/clustalw/.
2.7. Western Blot and Immunodetection. After SDS-PAGE,
gels were quickly washed in ultrapure H2O( m QH 2O)
(Millipore-Q system) and equilibrated for 15min in transfer
buﬀer containing 25mM TRIS, 192 mM glycine, and 80mM
urea. Subsequently, the proteins were electrotransferred onto
nitrocellulose membranes (0.2μm pore size, Protran BA 83,
Whatman) at constant 100V and 350mA for 1 hour at 4◦C
using Mini Trans-Blot (BioRad). The membranes were
quickly washed in mQ H2O, dried, wrapped in polypropy-
lene ﬁlm, and stored overnight at −20◦C.
On the following day, the membranes were washed for
15 minutes in 0.05% Tween in Tris-buﬀered saline (TTBS)
solution and blocked for 1 hour at room temperature (RT)
in 5% nonfat dry milk in TTBS. To detect α and β isoforms,
membranes were incubated with NB300-284 (1:1000, No-
vus Biologicals) or anti-Slow (1:1000, provided by BioTrend
and Novocastra) antibodies that recognized both cardiac
MyHC isoforms on WB membranes; for speciﬁc detection of
MyHCα, we used the BA.G5 antibody (1:5000, a kind gift by
ProfessorS.Schiaﬃno).Incubationswithprimaryantibodies
were performed for 1 hour at RT in the TTBS solution. TTBS
washing (3 × 15 minutes) preceded and followed the mem-
branes incubation with secondary anti-mouse IgG (Stabi-
lized Goat Anti-Mouse IgG (H+L) – HRP Conjugated, no.
32430, Thermo Scientiﬁc Pierce) diluted 1:1000 under the
same conditions as the primary antibodies. The membrane
signalsweredetectedbyenhancedchemiluminescence(ECL)
substrate (SuperSignal West Dura Extended Duration Sub-
strate, no. 34076, Thermo Scientiﬁc Pierce) and visualized by
the LAS-4000 system (Genetica, Fujiﬁlm).
2.8. Statistical Analysis. Obtained data were analyzed by the
GraphPad Prism 5 software. A one-way ANOVA and subseq-
uent Student-Newman-Keuls test were used for compari-
son of diﬀerences in normally distributed variables between
groups. Nonparametric Mann-Whitney’s U-test and Krus-
kal-Wallis’s test were used for a comparison of diﬀerences in
nonnormally distributed variables between groups. All data4 Journal of Biomedicine and Biotechnology
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Figure 1:SDS-PAGEseparationofcardiacMyHCisoformsfromleftventriclesofadulteuthyroid(EU),hypothyroid(HY),andhyperthyroid
(TH) Lewis rats. Control: soleus muscle (SOL) from the hypothyroid rat containing the MyHC1 isoform identical with cardiac MyHCβ.T h e
gel was silver stained (a) or stained by CBB+BBR (b) before MALDI TOF/TOF analysis.
EU HY TH SOL EU HY TH SOL
LV extract LV homogenate
(a)
EU HY TH SOL EU HY TH SOL
LV extract LV homogenate
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Figure 2: Western blot immunodetection of cardiac MyHC isoforms from left ventricle (LV) homogenates and extracts of adult euthyroid
(EU),hypothyroid(HY),andhyperthyroid(TH)Lewisrats.ThemembraneswerestainedbyNB300-284antibodyrecognizingbothMyHCα
and MyHCβ isoforms (a) or by BA.G5 antibody, which was solely speciﬁc for cardiac MyHCα isoform (b).
a r ee x p r e s s e da sm e a n± SD or as mean ± SEM. The dif-
ferences were considered as statistically signiﬁcant when P<
0.05.
3. Results andDiscussion
3.1.SeparationofCardiacMyHCIsoforms. TheSDS-PAGEof
cardiacMyHCisoformsrevealedthatamajorMyHCisoform
in EU and TH hearts was that with a greater mobility in
polyacrylamide gels, whereas HY LVs contained the predom-
inantly MyHC isoform with a lower mobility corresponding
to the mobility of slow-type MyHC1 isoform in control HY
SOL (Figures 1(a) and 1(b)). The same results were obtained
by homogenate as well as MyHC extract separations. Based
on the MyHC proﬁles observed in LVs at diﬀerent thyroid
states and in the control SOL, we assumed that MyHCα was
represented by the lower band with a higher mobility and
MyHCβ by the upper band with a lower mobility. The den-
sitometric quantiﬁcation of the obtained bands supported
our assumption, as the TH status was characterized by high-
er MyHCα expression, whereas the HY status signiﬁcantly
decreased MyHCα expression and increased MyHCβ expres-
sion when compared with EU and TH states (Table 1). Since
the observed mobilities of α and β isoforms in polyacryl-
amidegelswerequiteoppositetothosereportedinthelitera-
ture,wedecidedtorecheckourresultsbyWBimmunodetec-
tion and MALDI TOF/TOF analyses.
3.2. Identiﬁcation of α and β MyHC Isoforms by WB Immuno-
detection and MALDI TOF/TOF Analyses. The WB analysis
supported the conclusion based on results obtained by SDS-
PAGE.ThemonoclonalBA.G5antibody,showntobespeciﬁc
for rat MyHCα [44], marked only the lower band with a
highermobilityinEUandTHsamples,whiletheHYsamples
and SOL control remained unstained with this antibody
(Figure 2(b)). The NB300-284 antibody as well as anti-Slow
Table 1: Ratio of cardiac MyHCα/MyHCβ isoforms from left ven-
tricles of adult euthyroid (EU), hyperthyroid (TH), and hypothy-
roid (HY) Lewis rats. MyHC isoforms were separated by SDS-
PAGE, silver-stained, and quantiﬁed by densitometric evaluation
(Quantity One Software, BioRad). The data are expressed as
a mean ± SD, ∗signiﬁcantly diﬀerent from EU and TH, P<0.05,
number of animals = 5.
Thyroid status The ratio
EU 3.84 ± 0.72
TH 4.39 ± 0.63
HY 0.09 ± 0.05∗
antibodyrecognizedbothαandβ isoforms.Theseantibodies
marked the upper band with lower mobility in HY LVs and
SOL samples and the lower band in the case of EU and TH
rats (Figure 2(a)). The minor bands in all three thyroid states
were under the detection limit of the WB method. These re-
sults conﬁrm that cardiac LVs of EU and TH rats predomi-
nantlycontaintheMyHCαisoformshowinghighermobility,
whereas LVs of HY rats contain mainly the isoform MyHCβ
with the lower mobility.
The results of MALDI TOF/TOF analysis of EU, TH, HY,
and SOL samples highly matched the sequences of MyHCα
and MyHCβ and unambiguously identiﬁed both isoforms.
The overall sequence coverage for trypsin digested samples
was 52% for MyHCα and 58% for MyHCβ. Further experi-
ments with Lys-C and Asp-N endoproteinases were used to
increase the number of MyHCα isoform-speciﬁc (proteo-
typic) peptides and isoform-speciﬁc coverage which reached
about 40% and 10% using Lys-C and Asp-N digestion, res-
pectively. We highlighted the speciﬁc peptides resulting from
diﬀerent protease digestions in multiple sequence alignment
(ClustalW 1.83) of MyHCα and MyHCβ (Figure 3). Analysis
of HY samples digested by trypsin identiﬁed 27 peptides spe-
ciﬁc for MyHCβ (out of 61 in total). TH sample analysisJournal of Biomedicine and Biotechnology 5
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Figure 3:SpeciﬁcpeptidesobtainedbyMALDITOF/TOF(trypsin,Asp-N,andLys-Cproteases)andhighlightedinmultiplesequencealign-
ment (ClustalW 1.83) of MyHCα and MyHCβ: yellow: HY MyHCβ,b l u e :E UM y H C α,g r e e n :T HM y H C α, pink: overlap of EU MyHCα and
TH MyHCα. Red letters: speciﬁc amino acids for each MyHC isoform.
u s i n gt r y p s i nr e s u l t e di n1 4p e p t i d e s( o u to f4 1i nt o t a l )a n d
using Asp-N protease in 5 peptides speciﬁc for MyHCα (out
of 13 in total). Analysis of EU samples cleaved by Asp-N
endoproteinase identiﬁed 22 speciﬁc peptides (out of 51 in
total)andcleavedbyLys-Cendoproteinaseidentiﬁed16pep-
tidesspeciﬁcforMyHCα(outof37intotal).SOLtrypticdig-
estion followed by mass spectrometric identiﬁcation con-
ﬁrmed the presence of MyHCβ and obtained 27 speciﬁc pep-
tides out of a total of 41 total peptides that were homologous
with speciﬁc peptides of the HY sample. WB immunodetec-
tion as well as MALDI TOF/TOF analysis of Wistar EU rats
conﬁrmedthesameidentityofbothcardiacMyHCisoforms.
We have unambiguously shown that under our experi-
mental conditions, the isoform with higher mobility in SDS-
PAGE gels was the MyHCα, contrary to the prevailing
literature data, considering MyHCβ as being the faster iso-
form.
3.3.ExpressionofCardiacMyHCIsoformsunderAlteredThyr-
oid Status. The altered level of thyroid hormones is one of
the most important pathophysiological factors leading to
MyHCtransitionsandchangesinheartcontraction.Itisgen-
erally accepted that the increased levels of thyroid hormones
(hyperthyroidism) stimulate MyHCα expression, whereas
the decreased levels of thyroid hormones (hypothyroidism)
lead to the activation of MyHCβ expression [26–32]. It is
obvious from our study that only the LVs of HY rats contain
a signiﬁcant amount of MyHCβ, while for the LVs of EU and
TH rats the predominant isoform is the MyHCα.Journal of Biomedicine and Biotechnology 7
To estimate the eﬀect of thyroid status on the heart fun-
ction or ﬁtness of the rats, we measured the heart index
(heart mass in mg/body mass in g, expressed as a mean ±
SEM). In EU female and male rats, it was 3.23 ± 0.14 (n =
11) and 2.92 ± 0.06 (n = 1 3 ) ,r e s p e c t i v e l y .T h eT Hs t a t u sl e d
to cardiac hypertrophy, as the heart index signiﬁcantly in-
creased in female and male rats to 4.64 ± 0.23 (n = 11) and
3.78 ± 0.19 (n = 8), while the HY status resulted in cardiac
atrophy, as the index signiﬁcantly dropped to 2.9 ± 0.05 (n =
16) and 2.58 ± 0.11 (n = 10), respectively. Obviously, the
application of thyroid hormones in our experiments corres-
ponds to the physiological hypertrophy induced by chronic
exercise and characterized by increased expression of
MyHCα [45]. On the other hand, pathological hypertrophy,
caused by pressure and volume overload in spontaneous
hypertensive rats (SHR), leads to the shift from the MyHCα
to the MyHCβ [46]. Thyroid hormone applications as well
as physical training by swimming were able to prevent or re-
pair contractile protein abnormalities in pathological hyper-
trophy in rat hearts [46, 47].
3.4. Electrophoretic Mobility of Cardiac MyHC Isoforms. Our
experimentsshowedunexpectedresultsrelatingtothemobi-
lity of MyHC isoforms. Contrary to the literature data [17–
24], we observed higher mobility of the α and lower mobility
of the β isoform in polyacrylamide gels. However, these re-
sults can be considered reliable, the identity of the MyHC
isoforms was successfully veriﬁed by WB immunodetection
and mass spectrometry (MALDI TOF/TOF) methods. Both
analyses showed that MyHCα (no. 62029: 223.508.76 Da;
1939 AA; pI = 5.4500; charge = −28.5; Rat Gene Database)
represented by a lower band, moves with a higher mobility
in 12% polyacrylamide separating gels than MyHCβ (no.
62030: 222.899.28 Da; 1935 AA; pI = 5.4764; charge = −27;
RatGeneDatabase),representedbyanupperband(Figures1
and 2). Likewise, the control SOL sample analysis conﬁrmed
the position of MyHCβ as the upper band. Nevertheless, the
reason for the diﬀerent band position observed in our ex-
periments remains to be elucidated.
3.4.1.SDS-PAGEModiﬁcations. Factors aﬀectingtheelectro-
phoretic mobility of cardiac isoforms appear to have a cru-
cial importance for the observed mobility changes. We tested
various concentrations of acrylamide and glycerol and vari-
ous ratios of acrylamide and bisacrylamide, but all these
changes aﬀected only the quality of separation, not the posi-
tion of the bands.
It is known that the separation and mobility of cardiac
myosins by a native electrophoresis depend on several fac-
tors, such as the molecular mass, acidic and basic residues
[48], and helix content and amino acid composition [49],
and on the pH of the separating gel. Unlike the native gel
electrophoresis, the SDS-PAGE method under denaturating
conditions is supposed to separate cardiac MyHC isoforms
only by their molecular mass. The cardiac α and β isoforms
have nearly identical molecular masses (∼223kDa), so that
their separation is rather diﬃcult. Several recent works have
attempted to improve the electrophoretic resolution of the
cardiac MyHC isoforms. There were diﬀerent concentrations
of glycerol used: 5−45% [20], separating gels: 6% [24], 7%
[21, 23], 8% [20], and 12% [22], and diﬀerent acry-
lamide/bisacrylamide ratios: 37.5:1 [24], 50:1 [20, 21], and
200:1 [22]. All the mentioned papers, however, have re-
ported an improvement of separation, but no change in the
mobility of the isoforms.
For cardiac MyHC isoform separation, we used the
method according to Sant’Ana Pereira et al. [22]: 12% sep-
arating gel, 200:1 acrylamide/bisacrylamide ratio, constant
current 13mA, temperature 10◦C, and run time modiﬁed to
7 . 5h o u r s( 7h o u r so r i g i n a l l y ) .I ti si m p o rt a n tt on o t et h a tw e
used tissue processing according to Agbulut et al. [41] that
diﬀers signiﬁcantly from the procedure used by Sant’Ana
Pereira et al. [22] but in both cases the eventual activity of
proteases was excluded. Furthermore, the same results were
received with tissue homogenates and with MyHC extracts
(cf. Figure 2).
The MyHC isoform mobility apparently depends on two
forces acting against each other: the resistance and the elec-
trical force. Thus, one of the possible explanations of the un-
expected mobility observed might be the inﬂuence of the
amountofboundSDS.MyHCα,whichisslightlyheavier,has
4aminoacidsmorethanMyHCβ.Therefore,MyHCαshould
be covered by more SDS molecules and pulled through the
separating gel by a higher electrical force, which is in favor of
its higher mobility. The resistance, of the separating gel at
given concentration of acrylamide and bisacrylamide, in-
creases with the molecular weight of separated proteins. This
factor would then favor the higher mobility of MyHCβ with
a lower molecular weight. When these two factors were only
taken into account, then the higher mobility of MyHCα
could indicate that the electrical force have a greater impact
on MyHC mobility than the resistance of the polyacrylamide
gel.
3.4.2. Evaluation of Possible Mural Variability. A striking
transmural variation of ATPase activity and MyHC isoform
distribution was observed in rabbit [50]a n dr a t[ 51] hearts.
For our experiments, however, we have used longitudinal
stripes containing epicardial, midwall, and endocardial por-
tions in order to minimize any possible transmural variabil-
ity.
3.4.3. Possible Strain Diﬀerences. To the best of our knowl-
edge, this study was the ﬁrst analysis of cardiac MyHCs per-
formedoninbredLewisstrainrats.Theseanimalshavenatu-
rally higher levels of serum thyroxine compared with other
routinelyusedratstrains[52].Furthermore,inLewisratsthe
ﬁber type compositions of skeletal muscles are very unique.
When compared with other rat strains (Wistar, Sprague-
Dawley, Fisher 344, WBN/Kob, Lister Hooded, and SHR
rats),theirsoleusmusclesweretheslowestandtheirextensor
digitorum longus muscles were the fastest [53]. However, we
also analyzed cardiac MyHCs by the same methods in EU
Wistarrats,andthepositionsoftheMyHCsbandswerequite
similar to those obtained for the Lewis strain rats. In addi-
tion, no diﬀerences in cardiac MyHCs mobility among8 Journal of Biomedicine and Biotechnology
severalratstrainsinSDS-PAGEgels(SpragueDawley,Brown
Norway, Copenhagen, SHR, and Wistar rats) were seen by
Reiser et al. [54]. Strain diﬀerences can apparently aﬀect the
MyHC isoform ratio in the heart, but they obviously cannot
explain the observed switch of the band position of both
cardiac isoforms.
4. Conclusions
The data we obtained by SDS-PAGE in the three thyroid
states showed that only the left ventricles of HY rats con-
tained a signiﬁcant amount of MyHCβ, while the left ven-
tricles of EU and TH rats were almost devoid of this isoform,
expressing MyHCα as the major isoform. However, the high-
er mobility of MyHCα compared with that of MyHCβ was
contrarytotheliteraturedata.Therefore,theidentity ofboth
bands was conﬁrmed by western blot immunodetection us-
ing speciﬁc antibodies (BA.G5 and NB300-284) and by
MALDITOF/TOFthatshowedthespeciﬁcpeptidesresulting
fromdiﬀerentproteasedigestionsinmultiplesequencealign-
ment (ClustalW 1.83) of MyHCα and MyHCβ isoforms. The
reasonsfortheobservedunexpectedmobilityoftheisoforms
remain still unclear. The general conclusion from our results
is that the order of migration of the two cardiac MyHC iso-
forms must always be veriﬁed and not just assumed.
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